Compare ANDE & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ANDE | AUPH |
|---|---|---|
| Founded | 1947 | 1993 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.1B |
| IPO Year | 2005 | 2014 |
| Metric | ANDE | AUPH |
|---|---|---|
| Price | $70.65 | $16.18 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $75.00 | $17.25 |
| AVG Volume (30 Days) | 348.0K | ★ 924.7K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.03% | N/A |
| EPS Growth | N/A | ★ 5075.00 |
| EPS | ★ 2.62 | 0.53 |
| Revenue | ★ $11,008,928,000.00 | $283,055,000.00 |
| Revenue This Year | $7.28 | $17.54 |
| Revenue Next Year | $3.57 | $15.74 |
| P/E Ratio | ★ $26.45 | $30.34 |
| Revenue Growth | N/A | ★ 20.38 |
| 52 Week Low | $37.69 | $10.34 |
| 52 Week High | $82.11 | $19.25 |
| Indicator | ANDE | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 57.01 | 52.13 |
| Support Level | $68.57 | $14.61 |
| Resistance Level | $71.18 | $16.46 |
| Average True Range (ATR) | 2.44 | 0.47 |
| MACD | 0.76 | -0.03 |
| Stochastic Oscillator | 95.83 | 33.54 |
Andersons Inc is an agriculture and renewable fuels company. Its operations are classified into two reportable business segments: Agribusiness, which generates maximum revenue, and Renewables. The Agribusiness segment includes merchandising and managing logistics across various commodities, as well as being a manufacturer, distributor, and retailer of agricultural and related plant nutrients. The segment specializes in the movement of physical commodities such as whole grains, grain products, feed ingredients, and domestic fuel products, among other agricultural commodities. The Renewables segment mainly produces, purchases, and sells ethanol and co-products. Geographically, the company generates maximum revenue from the United States, followed by Canada, Mexico, and other markets.
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.